Biomarkers for Treatment Response in Advanced Prostate Cancer

Multiple treatment options with different mechanisms of action are currently available for the management of metastatic prostate cancer. However, the optimal use of these therapies—specifically, the sequencing of therapies—is not well defined. In order to obtain the best clinical outcomes, patients...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Samia Asif, Benjamin A. Teply
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	biomarkers prostate cancer predictive prognostic Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0fb3f4f5899244dd89585f92f0b83acd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0fb3f4f5899244dd89585f92f0b83acd
record_format	dspace
spelling	oai:doaj.org-article:0fb3f4f5899244dd89585f92f0b83acd2021-11-25T17:03:17ZBiomarkers for Treatment Response in Advanced Prostate Cancer10.3390/cancers132257232072-6694https://doaj.org/article/0fb3f4f5899244dd89585f92f0b83acd2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5723https://doaj.org/toc/2072-6694Multiple treatment options with different mechanisms of action are currently available for the management of metastatic prostate cancer. However, the optimal use of these therapies—specifically, the sequencing of therapies—is not well defined. In order to obtain the best clinical outcomes, patients need to be treated with the therapies that are most likely to provide benefit and avoid toxic therapies that are unlikely to be effective. Ideally, predictive biomarkers that allow for the selection of the therapies most likely to be of benefit would be employed for each treatment decision. In practice, biomarkers including tumor molecular sequencing, circulating tumor DNA, circulating tumor cell enumeration and androgen receptor characteristics, and tumor cell surface expression (PSMA), all may have a role in therapy selection. In this review, we define the established prognostic and predictive biomarkers for therapy in advanced prostate cancer and explore emerging biomarkers.Samia AsifBenjamin A. TeplyMDPI AGarticlebiomarkersprostate cancerpredictiveprognosticNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5723, p 5723 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biomarkers prostate cancer predictive prognostic Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	biomarkers prostate cancer predictive prognostic Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Samia Asif Benjamin A. Teply Biomarkers for Treatment Response in Advanced Prostate Cancer
description	Multiple treatment options with different mechanisms of action are currently available for the management of metastatic prostate cancer. However, the optimal use of these therapies—specifically, the sequencing of therapies—is not well defined. In order to obtain the best clinical outcomes, patients need to be treated with the therapies that are most likely to provide benefit and avoid toxic therapies that are unlikely to be effective. Ideally, predictive biomarkers that allow for the selection of the therapies most likely to be of benefit would be employed for each treatment decision. In practice, biomarkers including tumor molecular sequencing, circulating tumor DNA, circulating tumor cell enumeration and androgen receptor characteristics, and tumor cell surface expression (PSMA), all may have a role in therapy selection. In this review, we define the established prognostic and predictive biomarkers for therapy in advanced prostate cancer and explore emerging biomarkers.
format	article
author	Samia Asif Benjamin A. Teply
author_facet	Samia Asif Benjamin A. Teply
author_sort	Samia Asif
title	Biomarkers for Treatment Response in Advanced Prostate Cancer
title_short	Biomarkers for Treatment Response in Advanced Prostate Cancer
title_full	Biomarkers for Treatment Response in Advanced Prostate Cancer
title_fullStr	Biomarkers for Treatment Response in Advanced Prostate Cancer
title_full_unstemmed	Biomarkers for Treatment Response in Advanced Prostate Cancer
title_sort	biomarkers for treatment response in advanced prostate cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0fb3f4f5899244dd89585f92f0b83acd
work_keys_str_mv	AT samiaasif biomarkersfortreatmentresponseinadvancedprostatecancer AT benjaminateply biomarkersfortreatmentresponseinadvancedprostatecancer
_version_	1718412757353627648

Biomarkers for Treatment Response in Advanced Prostate Cancer

Ejemplares similares